How big is CorMedix, Inc.?

As of Jun 18, CorMedix, Inc. has a market capitalization of 945.48 million and reported net sales of 82.56 million and net profit of 17.17 million over the latest four quarters.

As of Jun 18, CorMedix, Inc. has a market capitalization of 945.48 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 82.56 million, while the sum of Net Profit for the same period is 17.17 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 84.66 million and Total Assets at 118.85 million.

What does CorMedix, Inc. do?

CorMedix, Inc. is a micro-cap pharmaceutical and medical device company focused on developing products for infectious and inflammatory diseases, with recent net sales of $39 million and a net profit of $21 million. The company has a market cap of $945.48 million and key financial metrics include a P/E ratio of 55.00 and a return on equity of 14.95%.

Overview:<BR>CorMedix, Inc. is a commercial pharmaceutical and medical device company that develops and commercializes products for the prevention and treatment of infectious and inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 39 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 21 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 945.48 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.67 <BR>Return on Equity: 14.95% <BR>Price to Book: 8.23<BR><BR>Contact Details:<BR>Address: 400 Connell Dr Ste 5000, BERKELEY HEIGHTS NJ: 07922-2809 <BR>Tel: 1 908 5179500 <BR>Website: http://www.cormedix.com

Should I buy, sell or hold CorMedix, Inc.?

Who are in the management team of CorMedix, Inc.?

As of March 2022, the management team of CorMedix, Inc. includes Myron Kaplan (Independent Chairman), Khoso Baluch (CEO), Paulo Costa, Gregory Duncan, Janet Dillione, Alan Dunton, and Steven Lefkowitz (all Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of CorMedix, Inc. includes the following individuals:<BR><BR>- Mr. Myron Kaplan, Independent Chairman of the Board<BR>- Mr. Khoso Baluch, Chief Executive Officer, Interim Principal Accounting Officer, Director<BR>- Mr. Paulo Costa, Director<BR>- Mr. Gregory Duncan, Director<BR>- Ms. Janet Dillione, Independent Director<BR>- Dr. Alan Dunton, Independent Director<BR>- Mr. Steven Lefkowitz, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is CorMedix, Inc. technically bullish or bearish?

As of September 10, 2025, CorMedix, Inc. shows a mildly bullish trend with daily moving averages supporting this stance, despite mixed signals from weekly indicators and strong long-term performance compared to the S&P 500.

As of 10 September 2025, the technical trend for CorMedix, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST are mildly bearish. The Bollinger Bands show a bearish signal on the weekly but mildly bullish on the monthly. The company has outperformed the S&P 500 significantly over the 1Y (61.35% vs. 17.14%) and 3Y (245.86% vs. 70.41%) periods, indicating strong long-term performance despite recent short-term weakness.

Is CorMedix, Inc. overvalued or undervalued?

As of October 17, 2025, CorMedix, Inc. has shifted from an attractive to a very attractive valuation grade, indicating it is undervalued with a PEG ratio of 0.42 and a high ROCE of 38.54%, despite a high P/E ratio of 55, and has outperformed the S&P 500 with a three-year return of 229.45%.

As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its valuation outlook. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests that the stock is trading at a lower price relative to its growth potential. Additionally, the P/E ratio stands at 55, which, while high, is offset by a robust ROCE of 38.54%, indicating efficient capital use.<BR><BR>In comparison to peers, CorMedix's valuation metrics are compelling; for instance, Xeris Biopharma Holdings, Inc. has a significantly negative P/E of -38.70, highlighting the relative strength of CorMedix. Furthermore, the EV to EBITDA ratio of 57.92 also contrasts sharply with the peer average, reinforcing the attractiveness of CorMedix's valuation. Despite recent underperformance in the short term, with a 1-week return of -5.13% compared to the S&P 500's 1.70%, the company's long-term performance over three years shows a remarkable return of 229.45%, significantly outpacing the index.